Bionano Genomics (BNGO) Cash & Current Investments (2017 - 2026)

Bionano Genomics has disclosed Cash & Current Investments across 10 years of filings, most recently posting $14.4 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $14.4 million, down 21.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.4 million (down 21.12% YoY), and the FY2025 annual result was $19.3 million, up 103.37% from the prior year.
• Cash & Current Investments came in at $14.4 million for Q1 2026 at Bionano Genomics, down from $19.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $216.4 million in Q1 2022 to a low of $5.1 million in Q4 2022.
• The 5-year median for Cash & Current Investments is $19.8 million (2024), against an average of $61.0 million.
• Across the five-year window, Cash & Current Investments slumped 97.97% in 2022 and jumped 942.33% in 2023, its largest moves.
• Bionano Genomics' Cash & Current Investments stood at $5.1 million in 2022, then surged by 942.33% to $53.1 million in 2023, then sank by 82.14% to $9.5 million in 2024, then soared by 103.37% to $19.3 million in 2025, then decreased by 25.37% to $14.4 million in 2026.
• The last three Cash & Current Investments figures came in at $14.4 million (Q1 2026), $19.3 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.